Physician profile
Allen D Bott
NPI 1770577652
$371,553.61
in general payments reported to CMS, 2019-2025
21 companies · $85K in 2025
The $85K reported for 2025 was more than what 99% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $58K · 2021: $51K · 2022: $34K · 2023: $37K · 2024: $30K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $79K · Consulting Fee: $35K · Honoraria: $21K · Travel and Lodging: $11K · Food and Beverage: $5,643 · Education: $219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $78,844.00 |
| Consulting Fee | $34,997.50 |
| Honoraria | $20,900.00 |
| Travel and Lodging | $10,999.87 |
| Food and Beverage | $5,643.40 |
| Education | $218.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $143,575.92 | 2019-2025 | Ingrezza, Ongentys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60,110.02 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $39,027.41 | 2023-2025 | Auvelity, Sunosi |
| Allergan, INC. | $34,321.65 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $23,559.34 | 2019-2023 | Rexulti, Abilify Maintena |
| Eisai INC. | $22,661.25 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $19,164.39 | 2019-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $14,876.00 | 2019 | |
| Abbvie INC. | $12,095.19 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Sunovion Pharmaceuticals INC. | $1,551.59 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $274.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $63.19 | 2025 | Cobenfy |
| Biogen, INC. | $60.91 | 2021-2022 | |
| Lundbeck LLC | $52.65 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $29.51 | 2024 | Crexont |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $26.75 | 2025 | Nuplazid |
| Alkermes, INC. | $26.19 | 2023 | Aristada, Lybalvi |
| Amgen INC. | $25.94 | 2019 | |
| Avanir Pharmaceuticals, INC. | $25.21 | 2020 | |
| Lilly USA, LLC | $14.34 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allen Bott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.